Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab Plus Venetoclax Plus Ibrutinib in CLL With TP53 Alterations
NCT07738887Phase 2Not yet recruiting
- Sponsor
- LYSARC
- Start
- Dec 2026
- Primary completion
- Dec 2029
- Countries
- 2
01
Overview
A Phase 2 trial of epcoritamab in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by LYSARC. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
epcoritamab
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT07738887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07738887.